Impax Asset Management Group
PETX

Impax Asset Management Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

Impax Asset Management Group’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-969,319
Closed -$3.49M – 306
2019
Q1 		$3.49M Buy
969,319
+933,262
+2,588% +$4.04M 0.05% 176
2018
Q4 		$221K Buy
+36,057
New +$220K ﹤0.01% 255

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $16.7B AUM 35.96% 1-Year Est. Return

Impax Asset Management Group's PETX Position: Q2 2019 in Review

Impax Asset Management Group sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 969,319 shares — an estimated $3.49M sold.

Impax Asset Management Group first reported a position in PETX in Q4 2018 and held it in 2 quarters. The position peaked at $3.49M in Q1 2019. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

  • Impax Asset Management Group reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Impax Asset Management Group sold 969,319 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $3.49M.
  • Impax Asset Management Group first reported a position in Aratana Therapeutics, Inc. in Q4 2018 and held it in 2 quarters.
  • Impax Asset Management Group's Aratana Therapeutics, Inc. position peaked at $3.49M in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Impax Asset Management Group's 13F filing for Q2 2019, filed 13 Aug 2019.